AMLX FY 2022 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M

Gross Profit

$19M86.5% margin

Operating Income

-$201M-905.7% margin

Net Income

-$198M-892.4% margin

EPS (Diluted)

$-2.98

Cash Flow

Operating Cash Flow

-$180M

Free Cash Flow

-$182M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$391M

Total Liabilities

$51M

Stockholders' Equity

$341M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$0	—
Gross Profit	$19M	$0	—
Operating Income	-$201M	-$83M	-143.5%
Net Income	-$198M	-$88M	-125.6%